Bioceltix S.A. (BCX.WA)
PLN 126.8
(2.26%)
PLN 126.8
(2.26%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -1.03 Million PLN | 2.38% |
| 2022 | -445.38 Thousand PLN | -18.15% |
| 2021 | -376.97 Thousand PLN | 90.25% |
| 2020 | -3.86 Million PLN | -11.11% |
| 2019 | -3.48 Million PLN | -92.73% |
| 2018 | -1.8 Million PLN | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -109.12 Thousand PLN | 9.3% |
| 2024 Q2 | -370.69 Thousand PLN | -239.7% |
| 2023 FY | -434.79 Thousand PLN | 2.38% |
| 2023 Q4 | -120.31 Thousand PLN | -10.7% |
| 2023 Q1 | -101.16 Thousand PLN | 12.13% |
| 2023 Q3 | -108.68 Thousand PLN | -3.87% |
| 2023 Q2 | -104.63 Thousand PLN | -3.43% |
| 2022 Q3 | -117.35 Thousand PLN | -4.99% |
| 2022 Q2 | -111.78 Thousand PLN | -10.55% |
| 2022 FY | -445.38 Thousand PLN | -18.15% |
| 2022 Q4 | -115.13 Thousand PLN | 1.89% |
| 2022 Q1 | -101.11 Thousand PLN | 96.23% |
| 2021 Q4 | -2.67 Million PLN | -2983.77% |
| 2021 FY | -376.97 Thousand PLN | 90.25% |
| 2021 Q3 | -86.9 Thousand PLN | 0.0% |
| 2020 FY | -3.86 Million PLN | -11.11% |
| 2019 FY | -3.48 Million PLN | -92.73% |
| 2018 FY | -1.8 Million PLN | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| BIOTON S.A. | 72.85 Million PLN | 101.425% |
| Captor Therapeutics Spolka Akcyjna | 6.9 Million PLN | 115.042% |
| Mabion S.A. | 114.58 Million PLN | 100.906% |
| Molecure S.A. | -4.1 Million PLN | 74.691% |
| NanoGroup S.A. | -79.01 Thousand PLN | -1213.737% |
| Pharmena S.A. | 5.84 Million PLN | 117.766% |
| Poltreg S.A. | -1.38 Million PLN | 25.157% |
| Pure Biologics Spólka Akcyjna | -2.57 Million PLN | 59.671% |
| Ryvu Therapeutics S.A. | 29.3 Million PLN | 103.542% |
| Synthaverse S.A. | 35.16 Million PLN | 102.952% |
| Urteste S.A. | -479 Thousand PLN | -116.717% |